In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novartis to buy NeuTec Pharma for £303.7mm

Executive Summary

In its fifth deal in about a week's time, Novartis has now agreed to acquire public company NeuTec Pharma (anti-infectives for the hospital market) for £10.50 ($19.53) in cash per NeuTec share, for a total of £303.7mm ($568mm).
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register